Modifiers of risk of hereditary breast cancer (original) (raw)

References

• Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117–1130.
  Article CAS Google Scholar
• Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C . (2005). Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 117: 988–991.
  Article CAS Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (1998). Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351: 1451–1467.
• Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K et al. (2005). Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case–control study. J Clin Oncol 23: 7491–7496.
  Article Google Scholar
• Fisher B, Constantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A et al. (1998). Tamoxifen for prevention of breast cancer; report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388.
  Article CAS Google Scholar
• Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL . (2006). Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res 8: R15 [E-pub ahead of print].
  Article Google Scholar
• Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P et al. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676–689.
  Article CAS Google Scholar
• Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M et al. (1995). Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation. Nat Genet 11: 428–433.
  Article CAS Google Scholar
• Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, et al., Hereditary Breast Cancer Clinical Study Group. (2006). Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118: 2281–2284.
  Article CAS Google Scholar
• Jernstrom H, Klug TL, Sepkovic DW, Bradlow HL, Narod SA . (2003). Predictors of the plasma ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups. Carcinogenesis 24: 991–1005.
  Article CAS Google Scholar
• Jernstrom H, Lubinksi J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C et al. (2004). Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96: 209–214.
  Article Google Scholar
• Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA et al. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609–1615.
  Article Google Scholar
• King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302: 643–646.
  Article CAS Google Scholar
• King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K et al. (2001). Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. J Am Med Assoc 286: 2251–2256.
  Article CAS Google Scholar
• Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C et al. (2005). Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control 16: 667–674.
  Article Google Scholar
• Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C et al. (2006). Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers (submitted).
• Kotsopoulos J, Narod SA . (2005). Towards a dietary prevention of hereditary breast cancer. Cancer Causes Control 16: 125–138.
  Article Google Scholar
• Kowalska E, Narod SA, Huzarski T, Zajaczek S, Huzarska J, Gorski B et al. (2005). Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation. Cancer Epidemiol Biomarkers Prev 14: 1302–1306.
  Article CAS Google Scholar
• Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E et al. (1997). Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 60: 1059–1067.
  CAS PubMed PubMed Central Google Scholar
• Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS et al. (1996). A polymorphic stop codon in BRCA2. Nat Genet 14: 253–254.
  Article CAS Google Scholar
• Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB et al. (2001). Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345: 159–164.
  Article CAS Google Scholar
• Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P et al. (2002). Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94: 1773–1779.
  Article CAS Google Scholar
• Narod SA, Lynch H, Conway T, Watson P, Feunteun J, Lenoir G . (1993). Increasing incidence of breast cancer in family with BRCA1 mutation. Lancet 341: 1101–1102.
  Article CAS Google Scholar
• Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H et al. (1998). Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 339: 424–428.
  Article CAS Google Scholar
• Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C et al. (2006). Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer 18: 1852.
  Google Scholar
• Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT et al. (1996). Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genet 12: 309–311.
  Article CAS Google Scholar
• Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al., PROSE Study Group. (2005). Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23: 7804–7810.
  Article CAS Google Scholar
• Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK et al. (1999). Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 64: 1371–1377.
  Article CAS Google Scholar
• Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L et al. (1999). Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91: 1475–1479.
  Article CAS Google Scholar
• Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK et al. (2001). Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 61: 5420–5424.
  CAS PubMed Google Scholar
• Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E et al. (2001). Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68: 700–710.
  Article CAS Google Scholar
• Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R et al. (2001). Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics 11: 635–638.
  Article CAS Google Scholar
• Russo J, Lynch H, Russo IH . (2001). Mammary gland architecture as a determining factor in the susceptibility of the human breast to cancer. Breast J 7: 277.
  Article Google Scholar
• Russo J, Rivera J, Russo IH . (1992). Influence of age and parity on the development of the human breast. Breast Cancer Res and Treat 23: 211–218.
  Article CAS Google Scholar
• The Breast Cancer Linkage Consortium (1999). Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310–1316.
• Thompson D, Easton D, Breast Cancer Linkage Consortium. (2001). Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68: 410–419.
  Article CAS Google Scholar
• Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L et al. (1997). Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60: 1079–1084.
  CAS PubMed PubMed Central Google Scholar
• Tryggvadottir L, Sigvaldason H, Olafsdottir GH, Jonasson JG, Jonsson T, Tulinius H et al. (2006). Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920–2000. J Natl Cancer Inst 98: 116–122.
  Article CAS Google Scholar
• Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch HT et al. (2005). A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev 14: 1534–1538.
  Article CAS Google Scholar

Download references